Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabina Cevoli

Showing results (101-110 of 142) with videos related to

Pageof 15
Sort By:
Headache|July 26, 2021
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 studyPiero Barbanti, Cinzia Aurilia, Sabina Cevoli, et al.
Headache|June 14, 2021
Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) projectPiero Barbanti, Luisa Fofi, Licia Grazzi, et al.
The Journal of Headache and Pain|December 19, 2021
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort studyFabrizio Vernieri, Nicoletta Brunelli, Roberta Messina, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 16, 2025
The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectivenessFabrizio Vernieri, Anna Ambrosini, Marco Bartolini, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 5, 2021
Real-life assessment of erenumab in refractory chronic migraine with medication overuse headacheUmberto Pensato, Carlo Baraldi, Valentina Favoni, et al.
The Journal of Headache and Pain|January 29, 2010
Headache, anxiety and depressive disorders: the HADAS studyEttore Beghi, Gennaro Bussone, Domenico D'Amico, et al.
Neurology and Therapy|February 8, 2024
Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)Fabrizio Vernieri, Luigi Francesco Iannone, Simona Guerzoni, et al.
The Journal of Headache and Pain|February 20, 2026
Whole blood DNA methylation signature of epigenetic aging in medication overuse headacheKatarzyna Malgorzata Kwiatkowska, Davide Mascarella, Francesca Ferraresi, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|August 27, 2020
Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)Fabrizio Vernieri, Claudia Altamura, Cinzia Aurilia, et al.
Fluids and Barriers of the CNS|September 7, 2022
In vivo assessment of Lewy body and beta-amyloid copathologies in idiopathic normal pressure hydrocephalus: prevalence and associations with clinical features and surgery outcomeGiulia Giannini, Simone Baiardi, Sofia Dellavalle, et al.
Pageof 15

Showing results (101-110 of 142) with videos related to

Sort By:
Pageof 15
Headache|July 26, 2021
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 studyPiero Barbanti, Cinzia Aurilia, Sabina Cevoli, et al.
Headache|June 14, 2021
Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) projectPiero Barbanti, Luisa Fofi, Licia Grazzi, et al.
The Journal of Headache and Pain|December 19, 2021
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort studyFabrizio Vernieri, Nicoletta Brunelli, Roberta Messina, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 16, 2025
The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectivenessFabrizio Vernieri, Anna Ambrosini, Marco Bartolini, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 5, 2021
Real-life assessment of erenumab in refractory chronic migraine with medication overuse headacheUmberto Pensato, Carlo Baraldi, Valentina Favoni, et al.
The Journal of Headache and Pain|January 29, 2010
Headache, anxiety and depressive disorders: the HADAS studyEttore Beghi, Gennaro Bussone, Domenico D'Amico, et al.
Neurology and Therapy|February 8, 2024
Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)Fabrizio Vernieri, Luigi Francesco Iannone, Simona Guerzoni, et al.
The Journal of Headache and Pain|February 20, 2026
Whole blood DNA methylation signature of epigenetic aging in medication overuse headacheKatarzyna Malgorzata Kwiatkowska, Davide Mascarella, Francesca Ferraresi, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|August 27, 2020
Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)Fabrizio Vernieri, Claudia Altamura, Cinzia Aurilia, et al.
Fluids and Barriers of the CNS|September 7, 2022
In vivo assessment of Lewy body and beta-amyloid copathologies in idiopathic normal pressure hydrocephalus: prevalence and associations with clinical features and surgery outcomeGiulia Giannini, Simone Baiardi, Sofia Dellavalle, et al.
Pageof 15